Expert US stock capital allocation track record and investment grade assessment for management quality evaluation. We evaluate how well management has historically deployed capital to create shareholder value.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Most Discussed Stocks
REGN - Stock Analysis
3652 Comments
991 Likes
1
Brees
Trusted Reader
2 hours ago
Why did I only see this now?
👍 266
Reply
2
Kyian
Elite Member
5 hours ago
Anyone else here just observing?
👍 289
Reply
3
Malique
Active Reader
1 day ago
Regret not noticing this sooner.
👍 103
Reply
4
Lundynn
Legendary User
1 day ago
Indices are moving sideways, reflecting investor caution in the absence of clear catalysts.
👍 109
Reply
5
Janiyaa
Senior Contributor
2 days ago
Professional US stock signals and market intelligence for investors seeking to maximize returns while maintaining disciplined risk controls. Our signal system combines multiple indicators to identify high-probability trade setups across various market conditions.
👍 243
Reply
© 2026 Market Analysis. All data is for informational purposes only.